INO
Inovio Pharmaceuticals, Inc.
There isn't enough reported data to score INO yet.
INO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Unavailable |
INO's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
INO PE Valuation
INO has no meaningful PE right now: it lost money over the past year.
INO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect INO's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
INO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.67 | +$1.88 |
| Q2 2026 | -$1.04 | +$1.53 |
| Q1 2026 | -$1.58 | +$1.57 |
| Q4 2025 | -$1.81 | +$2.14 |
| Q3 2025 | -$2.55 | +$1.89 |
| Q2 2025 | -$2.57 | +$2.54 |
| Q1 2025 | -$3.15 | +$2.33 |
| Q4 2024 | -$3.95 | +$2.14 |
INO is still losing money, but far less than before: $0.67 per share over the past year, against $20.64 at its worst in mid-2020.
INO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $117K | +14% |
| Q2 2024 | $100.8K | -55% |
| Q4 2023 | $102.7K | -18% |
| Q3 2023 | $388.4K | -96% |
| Q2 2023 | $226K | -71% |
| Q1 2023 | $114.9K | -42% |
| Q4 2022 | $124.7K | -85% |
| Q3 2022 | $9.2M | +3038% |
INO's revenue is growing: $298,901 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -6532% | N/A |
| Q1 2025 | -38337% | N/A |
| Q4 2024 | -17411% | +9276 points |
| Q2 2024 | -32946% | -16554 points |
| Q4 2023 | -26686% | +18191 points |
| Q3 2023 | -9153% | -8762 points |
| Q2 2023 | -16392% | -3116 points |
| Q1 2023 | -38238% | -2205 points |
INO's operating margin was −6532% last quarter, up 20154 points from the same quarter a year ago.
INO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.3M | +$6.4M |
| Q2 2026 | -$18M | +$2.8M |
| Q1 2026 | -$21.6M | +$5.3M |
| Q4 2025 | -$19.5M | +$165.9K |
| Q3 2025 | -$21.6M | +$5.8M |
| Q2 2025 | -$20.8M | +$7.8M |
| Q1 2025 | -$26.9M | +$1.9M |
| Q4 2024 | -$19.7M | +$6.6M |
INO has burned cash in almost every quarter: −$74M over the past year, against −$89M the year before.
INO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +21% | +17M shares |
| 1 year | +154% | +59.8M shares |
| 3 years | +358% | +77.1M shares |
| 5 years | +485% | +81.8M shares |
INO has 99M diluted shares, up 154% from a year ago.
INO Net Leverage
INO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
INO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.5 | Neutral |
| Stochastic | 32.9 | Neutral |
INO's weekly RSI is 57 (neutral) and its Stochastic is 33 (neutral).
INO PE vs Healthcare Sector
INO has no meaningful PE right now: it lost money over the past year.
INO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.08 | 35% above |
| 20 week MA | $1.10 | 33% above |
| 50 week MA | $1.35 | 8.1% above |
| 100 week MA | $1.67 | 13% below |
| 200 week MA | $4.98 | 71% below |
INO has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 71% below its 200-week average.
INO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.1 | $123.1 | +207% |
| 2021 | $123.1 | $73.0 | -41% |
| 2022 | $73.0 | $18.4 | -75% |
| 2023 | $18.4 | $6.12 | -67% |
| 2024 | $6.12 | $1.87 | -69% |
| 2025 | $1.87 | $2.29 | +22% |
| 2026 YTD | $2.29 | $1.46 | -36% |
INO's yearly returns have swung widely, from +207% in 2020 to −75% in 2022. It's down 36% so far in 2026.